JP2016503289A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503289A5
JP2016503289A5 JP2015538506A JP2015538506A JP2016503289A5 JP 2016503289 A5 JP2016503289 A5 JP 2016503289A5 JP 2015538506 A JP2015538506 A JP 2015538506A JP 2015538506 A JP2015538506 A JP 2015538506A JP 2016503289 A5 JP2016503289 A5 JP 2016503289A5
Authority
JP
Japan
Prior art keywords
protein
host cell
seq
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503289A (ja
JP6423351B2 (ja
Filing date
Publication date
Priority claimed from US13/663,527 external-priority patent/US10028998B2/en
Application filed filed Critical
Publication of JP2016503289A publication Critical patent/JP2016503289A/ja
Publication of JP2016503289A5 publication Critical patent/JP2016503289A5/ja
Application granted granted Critical
Publication of JP6423351B2 publication Critical patent/JP6423351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538506A 2012-10-30 2013-10-30 Fcγ受容体IIB変異体 Active JP6423351B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US13/663,527 2012-10-30
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018149864A Division JP2018186833A (ja) 2012-10-30 2018-08-09 Fcγ受容体IIB変異体

Publications (3)

Publication Number Publication Date
JP2016503289A JP2016503289A (ja) 2016-02-04
JP2016503289A5 true JP2016503289A5 (cg-RX-API-DMAC7.html) 2016-12-15
JP6423351B2 JP6423351B2 (ja) 2018-11-14

Family

ID=49679480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015538506A Active JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体
JP2018149864A Pending JP2018186833A (ja) 2012-10-30 2018-08-09 Fcγ受容体IIB変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018149864A Pending JP2018186833A (ja) 2012-10-30 2018-08-09 Fcγ受容体IIB変異体

Country Status (27)

Country Link
US (1) US10028998B2 (cg-RX-API-DMAC7.html)
EP (1) EP2914624B1 (cg-RX-API-DMAC7.html)
JP (2) JP6423351B2 (cg-RX-API-DMAC7.html)
KR (1) KR102170674B1 (cg-RX-API-DMAC7.html)
CN (1) CN104918955B (cg-RX-API-DMAC7.html)
AU (1) AU2013340831B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2887164C (cg-RX-API-DMAC7.html)
CL (1) CL2015001127A1 (cg-RX-API-DMAC7.html)
DK (1) DK2914624T3 (cg-RX-API-DMAC7.html)
EA (1) EA033437B9 (cg-RX-API-DMAC7.html)
ES (1) ES2628049T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170894T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032786T2 (cg-RX-API-DMAC7.html)
IL (1) IL238528A (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03206A (cg-RX-API-DMAC7.html)
LT (1) LT2914624T (cg-RX-API-DMAC7.html)
MX (1) MX359802B (cg-RX-API-DMAC7.html)
MY (1) MY173686A (cg-RX-API-DMAC7.html)
NZ (1) NZ706884A (cg-RX-API-DMAC7.html)
PH (1) PH12015500771B1 (cg-RX-API-DMAC7.html)
PL (1) PL2914624T3 (cg-RX-API-DMAC7.html)
PT (1) PT2914624T (cg-RX-API-DMAC7.html)
RS (1) RS56075B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201502749VA (cg-RX-API-DMAC7.html)
SI (1) SI2914624T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014068012A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
KR102138219B1 (ko) 2013-10-16 2020-07-28 수프레몰 게엠베하 자가면역 수포성 질환의 치료를 위한 가용성 Fc 감마 수용체
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えFcγRIIb
EP3810337A1 (de) * 2018-06-25 2021-04-28 BASF Coatings GmbH Verfahren zur herstellung einer optimierten beschichtung und mittels dieses verfahrens erhältliche beschichtung
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
AU2023367781A1 (en) 2022-10-25 2025-06-05 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
EP0833907A1 (en) 1995-06-23 1998-04-08 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1709073B1 (en) 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
PL1960427T3 (pl) 2005-12-13 2011-07-29 Suppremol Gmbh Multimeryczne polipeptydy receptora Fc
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

Similar Documents

Publication Publication Date Title
JP2016503289A5 (cg-RX-API-DMAC7.html)
WO2014118360A3 (en) Carbohydrate degrading polypeptide and uses thereof
WO2017060475A3 (en) Polypeptides
WO2018004308A3 (ko) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
WO2014202616A3 (en) Rasamsonia gene and use thereof
JP2014000092A5 (cg-RX-API-DMAC7.html)
WO2017070616A3 (en) Sexually transmitted disease vaccines
MX376770B (es) Composición detergente.
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
PH12014501726B1 (en) Glyphosate resistant plants and associated methods
WO2015014790A3 (en) Protease variants and polynucleotides encoding same
WO2015024739A3 (en) Detergent composition comprising protease variants
WO2014202622A3 (en) Rasamsonia gene and use thereof
WO2016062875A3 (en) Glucoamylase variants and polynucleotides encoding same
IN2015DN03206A (cg-RX-API-DMAC7.html)
AU2018253611A1 (en) Engineered pesticidal proteins
WO2015181119A3 (en) Lipase variants and polynucleotides encoding same
MY172218A (en) Nutritional compositions containing a peptide component with anti-flammatory properties and uses thereof
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
WO2015091959A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX388061B (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2015015518A3 (en) Process for production of insulin and insulin analogues
MX370305B (es) Proteína estructurante de hielo.
JP2010183921A5 (cg-RX-API-DMAC7.html)
WO2017089456A8 (en) Polypeptides having protease activity and polynucleotides encoding same